Levodopa responsiveness in disorders with parkinsonism: A review of the literature
Identifieur interne : 000E39 ( Istex/Corpus ); précédent : 000E38; suivant : 000E40Levodopa responsiveness in disorders with parkinsonism: A review of the literature
Auteurs : Radu Constantinescu ; Irene Richard ; Roger KurlanSource :
- Movement Disorders [ 0885-3185 ] ; 2007-11-15.
English descriptors
Abstract
A literature review was conducted to investigate whether or not levodopa (LD) responsiveness (LR) is a useful criterion in the diagnosis of parkinsonian disorders. Although LR does appear to differ among the parkinsonian disorders, there is considerable confusion in the literature. While most patients with Parkinson's disease (PD) have a sustained benefit from LD, a small minority of patients with documented PD do not respond. The literature suggests that the LR rate is higher for multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD) than based on published diagnostic criteria. Magnitude and duration of response to LD and tolerability (time course, type and distribution of dyskinesias, mental effects and motor worsening) may be useful features in distinguishing PD, MSA, PSP, and CBD. Efforts should be directed toward better defining LR when used for diagnostic purposes and in scientific publications. © 2007 Movement Disorder Society
Url:
DOI: 10.1002/mds.21578
Links to Exploration step
ISTEX:2D425B5E315A99C47905E1A12CECFE8F42F7F802Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Levodopa responsiveness in disorders with parkinsonism: A review of the literature</title><author><name sortKey="Constantinescu, Radu" sort="Constantinescu, Radu" uniqKey="Constantinescu R" first="Radu" last="Constantinescu">Radu Constantinescu</name><affiliation><mods:affiliation>Department of Neurology, University of Rochester School of Medicine, Rochester, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Richard, Irene" sort="Richard, Irene" uniqKey="Richard I" first="Irene" last="Richard">Irene Richard</name><affiliation><mods:affiliation>Department of Neurology, University of Rochester School of Medicine, Rochester, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Kurlan, Roger" sort="Kurlan, Roger" uniqKey="Kurlan R" first="Roger" last="Kurlan">Roger Kurlan</name><affiliation><mods:affiliation>Department of Neurology, University of Rochester School of Medicine, Rochester, New York, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:2D425B5E315A99C47905E1A12CECFE8F42F7F802</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1002/mds.21578</idno><idno type="url">https://api.istex.fr/document/2D425B5E315A99C47905E1A12CECFE8F42F7F802/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000E39</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Levodopa responsiveness in disorders with parkinsonism: A review of the literature</title><author><name sortKey="Constantinescu, Radu" sort="Constantinescu, Radu" uniqKey="Constantinescu R" first="Radu" last="Constantinescu">Radu Constantinescu</name><affiliation><mods:affiliation>Department of Neurology, University of Rochester School of Medicine, Rochester, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Richard, Irene" sort="Richard, Irene" uniqKey="Richard I" first="Irene" last="Richard">Irene Richard</name><affiliation><mods:affiliation>Department of Neurology, University of Rochester School of Medicine, Rochester, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Kurlan, Roger" sort="Kurlan, Roger" uniqKey="Kurlan R" first="Roger" last="Kurlan">Roger Kurlan</name><affiliation><mods:affiliation>Department of Neurology, University of Rochester School of Medicine, Rochester, New York, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-11-15">2007-11-15</date><biblScope unit="vol">22</biblScope><biblScope unit="issue">15</biblScope><biblScope unit="page" from="2141">2141</biblScope><biblScope unit="page" to="2148">2148</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">2D425B5E315A99C47905E1A12CECFE8F42F7F802</idno><idno type="DOI">10.1002/mds.21578</idno><idno type="ArticleID">MDS21578</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>levodopa</term><term>levodopa response</term><term>parkinsonian disorders</term><term>parkinsonism</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A literature review was conducted to investigate whether or not levodopa (LD) responsiveness (LR) is a useful criterion in the diagnosis of parkinsonian disorders. Although LR does appear to differ among the parkinsonian disorders, there is considerable confusion in the literature. While most patients with Parkinson's disease (PD) have a sustained benefit from LD, a small minority of patients with documented PD do not respond. The literature suggests that the LR rate is higher for multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD) than based on published diagnostic criteria. Magnitude and duration of response to LD and tolerability (time course, type and distribution of dyskinesias, mental effects and motor worsening) may be useful features in distinguishing PD, MSA, PSP, and CBD. Efforts should be directed toward better defining LR when used for diagnostic purposes and in scientific publications. © 2007 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Radu Constantinescu MD</name><affiliations><json:string>Department of Neurology, University of Rochester School of Medicine, Rochester, New York, USA</json:string></affiliations></json:item><json:item><name>Irene Richard MD</name><affiliations><json:string>Department of Neurology, University of Rochester School of Medicine, Rochester, New York, USA</json:string></affiliations></json:item><json:item><name>Roger Kurlan MD</name><affiliations><json:string>Department of Neurology, University of Rochester School of Medicine, Rochester, New York, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>parkinsonism</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>parkinsonian disorders</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>levodopa</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>levodopa response</value></json:item></subject><language><json:string>eng</json:string></language><abstract>A literature review was conducted to investigate whether or not levodopa (LD) responsiveness (LR) is a useful criterion in the diagnosis of parkinsonian disorders. Although LR does appear to differ among the parkinsonian disorders, there is considerable confusion in the literature. While most patients with Parkinson's disease (PD) have a sustained benefit from LD, a small minority of patients with documented PD do not respond. The literature suggests that the LR rate is higher for multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD) than based on published diagnostic criteria. Magnitude and duration of response to LD and tolerability (time course, type and distribution of dyskinesias, mental effects and motor worsening) may be useful features in distinguishing PD, MSA, PSP, and CBD. Efforts should be directed toward better defining LR when used for diagnostic purposes and in scientific publications. © 2007 Movement Disorder Society</abstract><qualityIndicators><score>6.764</score><pdfVersion>1.3</pdfVersion><pdfPageSize>594 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>997</abstractCharCount><pdfWordCount>6105</pdfWordCount><pdfCharCount>38134</pdfCharCount><pdfPageCount>8</pdfPageCount><abstractWordCount>147</abstractWordCount></qualityIndicators><title>Levodopa responsiveness in disorders with parkinsonism: A review of the literature</title><genre><json:string>Serial article</json:string></genre><host><volume>22</volume><pages><total>8</total><last>2148</last><first>2141</first></pages><issn><json:string>0885-3185</json:string></issn><issue>15</issue><subject><json:item><value>Review</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2007</publicationDate><copyrightDate>2007</copyrightDate><doi><json:string>10.1002/mds.21578</json:string></doi><id>2D425B5E315A99C47905E1A12CECFE8F42F7F802</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/2D425B5E315A99C47905E1A12CECFE8F42F7F802/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/2D425B5E315A99C47905E1A12CECFE8F42F7F802/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/2D425B5E315A99C47905E1A12CECFE8F42F7F802/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Levodopa responsiveness in disorders with parkinsonism: A review of the literature</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>2007</date></publicationStmt><notesStmt><note type="content">*This article is part of the journal's CME program. The CME form can be found on page 2295 and is available online at http://www.movementdisorders.org/education/activities.html</note><note>Parkinson's Disease Data and Organizing Center (PD‐DOC)</note><note>NINDS - No. U01 NS050095;</note><note>National Parkinson Foundation Center of Excellence at the University of Rochester</note><note>NINDS Career Development Award - No. 1 K23NS02184;</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Levodopa responsiveness in disorders with parkinsonism: A review of the literature</title><author><persName><forename type="first">Radu</forename><surname>Constantinescu</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Neurology, University of Rochester School of Medicine, Rochester, New York, USA</affiliation></author><author><persName><forename type="first">Irene</forename><surname>Richard</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Neurology, University of Rochester School of Medicine, Rochester, New York, USA</affiliation></author><author><persName><forename type="first">Roger</forename><surname>Kurlan</surname><roleName type="degree">MD</roleName></persName><note type="correspondence"><p>Correspondence: Mt. Hope Professional Building, 1351 Mt. Hope Avenue, Suite 100, Rochester, NY 14618</p></note><affiliation>Department of Neurology, University of Rochester School of Medicine, Rochester, New York, USA</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-11-15"></date><biblScope unit="vol">22</biblScope><biblScope unit="issue">15</biblScope><biblScope unit="page" from="2141">2141</biblScope><biblScope unit="page" to="2148">2148</biblScope></imprint></monogr><idno type="istex">2D425B5E315A99C47905E1A12CECFE8F42F7F802</idno><idno type="DOI">10.1002/mds.21578</idno><idno type="ArticleID">MDS21578</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2007</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>A literature review was conducted to investigate whether or not levodopa (LD) responsiveness (LR) is a useful criterion in the diagnosis of parkinsonian disorders. Although LR does appear to differ among the parkinsonian disorders, there is considerable confusion in the literature. While most patients with Parkinson's disease (PD) have a sustained benefit from LD, a small minority of patients with documented PD do not respond. The literature suggests that the LR rate is higher for multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD) than based on published diagnostic criteria. Magnitude and duration of response to LD and tolerability (time course, type and distribution of dyskinesias, mental effects and motor worsening) may be useful features in distinguishing PD, MSA, PSP, and CBD. Efforts should be directed toward better defining LR when used for diagnostic purposes and in scientific publications. © 2007 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>parkinsonism</term></item><item><term>Parkinson's disease</term></item><item><term>parkinsonian disorders</term></item><item><term>levodopa</term></item><item><term>levodopa response</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Review</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2006-05-19">Received</change><change when="2007-04-16">Registration</change><change when="2007-11-15">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/2D425B5E315A99C47905E1A12CECFE8F42F7F802/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="150"><doi origin="wiley" registered="yes">10.1002/mds.v22:15</doi><numberingGroup><numbering type="journalVolume" number="22">22</numbering><numbering type="journalIssue">15</numbering></numberingGroup><coverDate startDate="2007-11-15">15 November 2007</coverDate></publicationMeta><publicationMeta level="unit" type="reviewArticle" position="10" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.21578</doi><idGroup><id type="unit" value="MDS21578"></id></idGroup><countGroup><count type="pageTotal" number="8"></count></countGroup><titleGroup><title type="articleCategory">Review</title><title type="tocHeading1">Reviews</title></titleGroup><copyright ownership="thirdParty">Copyright © 2007 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2006-05-19"></event><event type="manuscriptRevised" date="2007-03-19"></event><event type="manuscriptAccepted" date="2007-04-16"></event><event type="publishedOnlineEarlyUnpaginated" date="2007-05-29"></event><event type="firstOnline" date="2007-05-29"></event><event type="publishedOnlineFinalForm" date="2007-11-27"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.6 mode:FullText source:FullText result:FullText" date="2010-04-21"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">2141</numbering><numbering type="pageLast">2148</numbering></numberingGroup><correspondenceTo>Mt. Hope Professional Building, 1351 Mt. Hope Avenue, Suite 100, Rochester, NY 14618</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS21578.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="0"></count><count type="referenceTotal" number="76"></count><count type="wordTotal" number="6665"></count></countGroup><titleGroup><title type="main" xml:lang="en">Levodopa responsiveness in disorders with parkinsonism: A review of the literature<link href="#fn1"></link></title><title type="short" xml:lang="en">Levodopa Responsiveness in Disorders with Parkinsonism</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Radu</givenNames><familyName>Constantinescu</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Irene</givenNames><familyName>Richard</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Roger</givenNames><familyName>Kurlan</familyName><degrees>MD</degrees></personName><contactDetails><email>roger kurlan@urmc.rochester.edu</email></contactDetails></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, University of Rochester School of Medicine, Rochester, New York, USA</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">parkinsonism</keyword><keyword xml:id="kwd2">Parkinson's disease</keyword><keyword xml:id="kwd3">parkinsonian disorders</keyword><keyword xml:id="kwd4">levodopa</keyword><keyword xml:id="kwd5">levodopa response</keyword></keywordGroup><fundingInfo><fundingAgency>Parkinson's Disease Data and Organizing Center (PD‐DOC)</fundingAgency></fundingInfo><fundingInfo><fundingAgency>NINDS</fundingAgency><fundingNumber>U01 NS050095</fundingNumber></fundingInfo><fundingInfo><fundingAgency>National Parkinson Foundation Center of Excellence at the University of Rochester</fundingAgency></fundingInfo><fundingInfo><fundingAgency>NINDS Career Development Award</fundingAgency><fundingNumber>1 K23NS02184</fundingNumber></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>A literature review was conducted to investigate whether or not levodopa (LD) responsiveness (LR) is a useful criterion in the diagnosis of parkinsonian disorders. Although LR does appear to differ among the parkinsonian disorders, there is considerable confusion in the literature. While most patients with Parkinson's disease (PD) have a sustained benefit from LD, a small minority of patients with documented PD do not respond. The literature suggests that the LR rate is higher for multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD) than based on published diagnostic criteria. Magnitude and duration of response to LD and tolerability (time course, type and distribution of dyskinesias, mental effects and motor worsening) may be useful features in distinguishing PD, MSA, PSP, and CBD. Efforts should be directed toward better defining LR when used for diagnostic purposes and in scientific publications. © 2007 Movement Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p>This article is part of the journal's CME program. The CME form can be found on page 2295 and is available online at <url href="http://www.movementdisorders.org/education/activities.html">http://www.movementdisorders.org/education/activities.html</url></p></note></noteGroup></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 4-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Levodopa responsiveness in disorders with parkinsonism: A review of the literature</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Levodopa Responsiveness in Disorders with Parkinsonism</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Levodopa responsiveness in disorders with parkinsonism: A review of the literature</title></titleInfo><name type="personal"><namePart type="given">Radu</namePart><namePart type="family">Constantinescu</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University of Rochester School of Medicine, Rochester, New York, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Irene</namePart><namePart type="family">Richard</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University of Rochester School of Medicine, Rochester, New York, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Roger</namePart><namePart type="family">Kurlan</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University of Rochester School of Medicine, Rochester, New York, USA</affiliation><description>Correspondence: Mt. Hope Professional Building, 1351 Mt. Hope Avenue, Suite 100, Rochester, NY 14618</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">reviewArticle</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2007-11-15</dateIssued><dateCaptured encoding="w3cdtf">2006-05-19</dateCaptured><dateValid encoding="w3cdtf">2007-04-16</dateValid><copyrightDate encoding="w3cdtf">2007</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="references">76</extent><extent unit="words">6665</extent></physicalDescription><abstract lang="en">A literature review was conducted to investigate whether or not levodopa (LD) responsiveness (LR) is a useful criterion in the diagnosis of parkinsonian disorders. Although LR does appear to differ among the parkinsonian disorders, there is considerable confusion in the literature. While most patients with Parkinson's disease (PD) have a sustained benefit from LD, a small minority of patients with documented PD do not respond. The literature suggests that the LR rate is higher for multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD) than based on published diagnostic criteria. Magnitude and duration of response to LD and tolerability (time course, type and distribution of dyskinesias, mental effects and motor worsening) may be useful features in distinguishing PD, MSA, PSP, and CBD. Efforts should be directed toward better defining LR when used for diagnostic purposes and in scientific publications. © 2007 Movement Disorder Society</abstract><note type="content">*This article is part of the journal's CME program. The CME form can be found on page 2295 and is available online at http://www.movementdisorders.org/education/activities.html</note><note type="funding">Parkinson's Disease Data and Organizing Center (PD‐DOC)</note><note type="funding">NINDS - No. U01 NS050095; </note><note type="funding">National Parkinson Foundation Center of Excellence at the University of Rochester</note><note type="funding">NINDS Career Development Award - No. 1 K23NS02184; </note><subject lang="en"><genre>Keywords</genre><topic>parkinsonism</topic><topic>Parkinson's disease</topic><topic>parkinsonian disorders</topic><topic>levodopa</topic><topic>levodopa response</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Review</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><detail type="issue"><caption>no.</caption><number>15</number></detail><extent unit="pages"><start>2141</start><end>2148</end><total>8</total></extent></part></relatedItem><identifier type="istex">2D425B5E315A99C47905E1A12CECFE8F42F7F802</identifier><identifier type="DOI">10.1002/mds.21578</identifier><identifier type="ArticleID">MDS21578</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2007 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E39 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000E39 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:2D425B5E315A99C47905E1A12CECFE8F42F7F802
|texte= Levodopa responsiveness in disorders with parkinsonism: A review of the literature
}}
| This area was generated with Dilib version V0.6.23. |  |